Serum and Urinary sCD163 in IgA Nephropathy (NCT07754019) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Serum and Urinary sCD163 in IgA Nephropathy
Turkey (Türkiye)87 participantsStarted 2025-02-03
Plain-language summary
IgA nephropathy is a common primary glomerular disease with a highly variable clinical course. Soluble CD163 is a marker associated with monocyte and macrophage activation and may reflect inflammatory activity in kidney disease. This single-center observational study aims to evaluate the associations of serum and urinary soluble CD163 levels with clinical disease activity, histopathologic severity, and renal prognosis in patients with IgA nephropathy. Clinical, laboratory, and kidney biopsy findings will be assessed together with serum and urinary soluble CD163 measurements. Participants will also be followed for renal outcomes, including changes in kidney function and proteinuria. The study is expected to clarify whether soluble CD163 may serve as a noninvasive biomarker of disease activity and prognosis in IgA nephropathy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* \- Age 18 years or older
* Biopsy-proven primary IgA nephropathy or primary focal segmental glomerulosclerosis
* Stable kidney function with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m²
* Availability of serum and urine samples for soluble CD163 measurement
* Availability of relevant demographic, clinical, laboratory, histopathologic, and follow-up data
* For the healthy control group: age- and sex-matched individuals without known chronic disease and with normal kidney function
* Written informed consent
Exclusion Criteria:
* \- Secondary IgA nephropathy or secondary focal segmental glomerulosclerosis
* Active infection
* Acute kidney injury
* End-stage kidney disease or ongoing dialysis treatment
* Estimated glomerular filtration rate below 15 mL/min/1.73 m²
* Recent use of corticosteroids or immunosuppressive therapy
* Pregnancy
* Active malignancy or history of malignancy
* Inadequately stored or unavailable serum and/or urine samples
* Missing essential clinical, laboratory, histopathologic, or follow-up data
* Absence of written informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Comparison of Serum and Urinary Soluble CD163 Levels Among IgAN, FSGS, and Healthy Control Groups